Aysun Fatma Akkuş, Osman Köstek, Muhammet Bekir Hacıoğlu, Bülent Erdoğan, İrfan Çiçin, Sernaz Topaloğlu
Eurasian Journal of Medical Investigation - 2025;9(3):152-160
Objectives: This retrospective study aimed to identify factors influencing disease recurrence and survival in patients with triple-negative breast cancer (TNBC). Methods: The study included 69 patients who were admitted to the medical oncology clinic of Trakya University between January 1, 2012, and March 1, 2019. Clinicopathological characteristics, recurrence, survival factors, and treatment approaches were evaluated. Univariate and multivariate analyses were performed. Data were expressed as mean+/-SD, with comparisons made using the independent t-test for parametric variables and Chi-square test for non-parametric variables. Survival was analyzed using Kaplan-Meier and Cox regression, with a significance level of p<0.05. Results: Of the 69 patients, 11 received neoadjuvant therapy, and 58 received adjuvant therapy. The median disease-free survival was 50.2 months, and the median overall survival was 123.1 months. Disease-free survival was shorter in patients with Ki-67 >30% (p=0.006). Advanced age (>60 years) and neoadjuvant therapy were independent predictors of disease-free survival, with overall survival being lower in patients over 60. Conclusion: Genetic counseling for BRCA mutation testing is recommended for this patient group. No significant findings were observed for other clinical and demographic factors. Due to the retrospective nature and small sample size, further studies with larger patient groups are needed.
